Faulding Canada

Faulding Canada was the Canadian subsidiary of the Australian pharmaceutical company F.H. Faulding & Co., which specialized in the development and distribution of generic injectable medicines. The company was particularly well-regarded for its portfolio of oncology products and hospital-based therapies, providing cost-effective alternatives for critical care. Following the acquisition of its parent company by Mayne Group in 2001, the Canadian operations were rebranded and eventually integrated into Hospira in 2007. Today, the legacy of Faulding Canada exists within Pfizer's global sterile injectables and hospital business units. During its peak, it was a vital supplier to the Canadian healthcare system, focusing on high-quality manufacturing of complex generic formulations.